Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
Version 6 2021-10-20, 09:37
Version 5 2021-10-15, 13:18
Version 4 2021-10-15, 13:15
Version 3 2021-10-15, 08:14
Version 2 2021-04-21, 15:42
Version 1 2021-04-15, 16:19
media
posted on 2021-10-20, 09:37 authored by Adis journalson behalf of, Andrew M Blumenfeld, Benjamin M Frishberg, Jack D Schim, Ashley Iannone, Gary Schneider, Larisa Yedigarova, Aubrey Manack Adams<p><strong>Article full
text</strong></p>
<p> </p>
<p>The article associated with this page
has been accepted for online publication and is in the final stages of
production. The link to the full text will be made available on this page in
the next few days.</p>
<p> </p>
<p>The above summary slide represents
the opinions of the authors. For a full list of declarations, including funding
and author disclosure statements, please see the full text online (see “read
the peer-reviewed publication” opposite). </p>
<p>© The authors, CC-BY-NC 2021.</p>
